Consultations on evidence synthesis documents — page 2
33 consultations on documents of this type.
Consultations
-
Consultation on the draft of this intervention review, which registers the question: In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse…
13 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
7 submissions1 not accepted -
Consultation on the draft of this safety review, which registers the question: What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
12 submissions2 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
11 submissions -
Consultation on the draft of this safety review, which registers the question: Do incretin-based therapies increase the incidence of acute pancreatitis?
10 submissions3 not accepted -
Consultation on the draft of this methodological review, which registers the question: For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and…
16 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the…
16 submissions1 not accepted -
Consultation on the draft of this methodological review, which registers the question: What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an…
10 submissions2 not accepted -
Consultation on the draft of this network meta-analysis, which registers the question: Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable…
15 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
9 submissions1 not accepted -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?
16 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
10 submissions -
Consultation on the draft of this intervention review, which registers the question: In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on…
4 submissions
page 2 of 2